Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 21NET 2Endocrine 2Sarcoma 1Other neoplasm 1

Conditions

Rectal Neuroendocrine Tumors 2

Interventions

lutetium Lu 177 dotatate 30Magnetic Resonance Spectroscopy 25pembrolizumab 21Specimen Handling 18Nivolumab 17cabozantinib 14lenvatinib 12Everolimus 12trametinib 11gallium Ga 68 dotatate 10dabrafenib 10Ipilimumab 10Carboplatin 10Cisplatin 8atezolizumab 7Temozolomide 7Lutetium-177 7X-Rays 6Etoposide 6Capecitabine 6surufatinib 5lanreotide 5fluorodopa F 18 5cemiplimab 5Vemurafenib 5Paclitaxel 5Octreotide 5Lutetium 5Fluorodeoxyglucose F18 5Disulfides 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Endoscopic Mucosal Resection × Endocrine × 1 year × Clear all
NCT07612748 2026-06-03

Two Different Endoscopic Treatments for Rectal Neuroendocrine Neoplasms

Jilin University

Phase NA Recruiting
483 enrolled
EndocrineGastrointestinalNET

Rectal Neuroendocrine Tumors

NCT07373015 2026-01-28

Modified Double Snare Assisted EMR (mDS-EMR) VS ESD for Rectal Neuroendocrine Tumors Smaller Than 1cm

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase NA Not yet recruiting
118 enrolled
EndocrineGastrointestinalNET

Rectal Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡